The single ascending dose trial enrolled lean or overweight men with an average BMI of 26.6. Study participants were then ...

Zealand is po­si­tion­ing the drug as a po­ten­tial stand­alone re­place­ment for GLP-1s or as the first med­i­cine that ...

During the company's earnings call, Viking CEO Brian Lian told investors that one of the goals from the dual ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Metsera also has clinical trials underway for an injectable amylin analog called MET-233i and an oral GLP-1 peptide called ...